datasetposted on 2022-03-21, 10:09 authored by Figshare Future Science GroupFigshare Future Science Group, Lei ZhangLei Zhang, Yijiao Qian, Jinnan Li, Chenwei Cui, Lu ChenLu Chen, Shuli Qu, Shun Lu
Appendix Table 1： Literature search strategies
Appendix Table 2: PICOS criteria to assess studies for the SLR
Appendix Table 3: Baseline characteristics and main outcomes of included trials
Table 3.1 Baseline characteristics of included trials
Table 3.2 Main outcomes of included trials
Indirect comparison of sintilimab and other PD-(L)1 for first-line treatment of non-squamous non-small-cell lung cancer
Objective: To evaluate sintilimab compared with other PD-(L)1 inhibitors in combination with platinum-based doublet chemotherapy as the first-line treatment of non-squamous non-small-cell lung cancer (nsqNSCLC).
Methods: A frequentist meta-analysis was used to compare outcomes including progression-free survival (PFS), OS (overall survival), objective response rate, time to response and safety profile.
Results: Sintilimab-combination arm had a comparable PFS with that of pembrolizumab-combination arm (HR=1.00, 95% CI: 0.71, 1.41), atezolizumab-combination arm (HR=0.81, 95% CI: 0.59, 1.10), tislelizumab-combination arm (HR= 0.75, 95% CI: 0.48, 1.16), camrelizumab-combination arm (HR=0.80, 95% CI: 0.54, 1.20) and nivolumab-combination arm (HR=0.72, 95% CI: 0.51, 1.02). Any grade or grade ≥3 adverse event was comparable between PD-(L)1 inhibitors.
Conclusion: Sintilimab showed comparable efficacy and safety profile when comparing with other PD-(L)1 inhibitors combined with PT-DC as the first-line treatment of locally advanced or metastatic nsqNSCLC.